398 related articles for article (PubMed ID: 28652456)
1. Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects.
Bargagli E; Bonti V; Ferrari K; Rosi E; Bindi A; Bartolucci M; Chiara M; Voltolini L
In Vivo; 2017; 31(4):773-777. PubMed ID: 28652456
[TBL] [Abstract][Full Text] [Related]
2. Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review.
Shiratori T; Tanaka H; Tabe C; Tsuchiya J; Ishioka Y; Itoga M; Taima K; Takanashi S; Tasaka S
Thorac Cancer; 2020 Jun; 11(6):1720-1723. PubMed ID: 32285615
[TBL] [Abstract][Full Text] [Related]
3. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities.
King CS; Nathan SD
Lancet Respir Med; 2017 Jan; 5(1):72-84. PubMed ID: 27599614
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
5. Remarkable response of non-small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis.
Kai Y; Matsuda M; Fukuoka A; Hontsu S; Yamauchi M; Yoshikawa M; Muro S
Thorac Cancer; 2021 May; 12(9):1457-1460. PubMed ID: 33742758
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
8. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.
Ballester B; Milara J; Cortijo J
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704051
[TBL] [Abstract][Full Text] [Related]
9. Guidelines for the medical treatment of idiopathic pulmonary fibrosis.
Xaubet A; Molina-Molina M; Acosta O; Bollo E; Castillo D; Fernández-Fabrellas E; Rodríguez-Portal JA; Valenzuela C; Ancochea J
Arch Bronconeumol; 2017 May; 53(5):263-269. PubMed ID: 28292522
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
11. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.
Bonella F; Stowasser S; Wollin L
Drug Des Devel Ther; 2015; 9():6407-19. PubMed ID: 26715838
[TBL] [Abstract][Full Text] [Related]
12. [Can nivolumab be used safely in idiopathic pulmonary fibrosis?].
Duchemann B; Didier M; Pailler MC; Brillet PY; Kambouchner M; Uzunhan Y; Freynet O; Chouahnia K; Zelek L; Nunes H
Rev Mal Respir; 2019 Feb; 36(2):209-213. PubMed ID: 30686563
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease.
Barczi E; Starobinski L; Kolonics-Farkas A; Eszes N; Bohacs A; Vasakova M; Hejduk K; Müller V
Adv Ther; 2019 May; 36(5):1221-1232. PubMed ID: 30877478
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis.
Shimomura I; Abe M; Li Y; Tsushima K; Sakao S; Tanabe N; Ikusaka M; Tatsumi K
Intern Med; 2019 Apr; 58(7):965-968. PubMed ID: 30568123
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function.
Zhang X; Li W; Li C; Zhang J; Su Z
BMC Pulm Med; 2021 Apr; 21(1):122. PubMed ID: 33858421
[TBL] [Abstract][Full Text] [Related]
16. Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management.
van Cleemput J; Sonaglioni A; Wuyts WA; Bengus M; Stauffer JL; Harari S
Adv Ther; 2019 Feb; 36(2):298-317. PubMed ID: 30554332
[TBL] [Abstract][Full Text] [Related]
17. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
[TBL] [Abstract][Full Text] [Related]
18. [Expert Knowledge and Supporting Advice for the Clinical Use of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis].
Behr J; Günther A; Kreuter M; Koschel D; Prasse A; Pfeifer M; Costabel U
Pneumologie; 2017 Sep; 71(9):567-579. PubMed ID: 28772332
[TBL] [Abstract][Full Text] [Related]
19. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]